menu
    • menu
    [{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"NRG5051","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRG Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"NRG Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"5","companyTruncated":"NRG Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"SV Health Investors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"NRG5051","moa":"mPTP","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRG Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"NRG Therapeutics \/ SV Health Investors","highestDevelopmentStatusID":"5","companyTruncated":"NRG Therapeutics \/ SV Health Investors"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"ALS Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRG Therapeutics \/ ALS Foundation","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ ALS Foundation"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"NRG Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ Omega Funds"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRG Therapeutics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRG Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research"}]

    Find Clinical Drug Pipeline Developments & Deals by NRG Therapeutics

    Menu

    NRG Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NRG Therapeutics

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed

                            NRG Therapeutics

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NRG5051

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : SV Health Investors

                            Deal Size : $67.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            NRG Therapeutics Announces Oversubscribed Series B Financing

                            Details : The financing will enable NRG Therapeutics to deliver clinical proof of concept in ALS/MND with NRG5051, a first-in-class, oral inhibitor of the mitochondrial permeability transition pore (mPTP).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 08, 2025

                            Lead Product(s) : NRG5051

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : SV Health Investors

                            Deal Size : $67.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NRG Therapeutics

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed

                            NRG Therapeutics

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NRG5051

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $5.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NRG Selects NRG5051 Candidate with Michael J. Fox Foundation Grant for mPTP

                            Details : NRG5051 is a first-in-class inhibitor of the mPTP and is designed to penetrate the brain when taken orally. It is being evaluated for the treatment of Parkinson's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 31, 2024

                            Lead Product(s) : NRG5051

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $5.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NRG Therapeutics

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed

                            NRG Therapeutics

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : ALS Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NRG Therapeutics Receives Grant from Target ALS for ALS/MND Treatments

                            Details : The funding will be used to support the discovery program focused on developing mPTP inhibitors as novel treatments for amyotrophic lateral sclerosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 05, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : ALS Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            NRG Therapeutics

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed

                            NRG Therapeutics

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $0.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinsonâ€...

                            Details : The funding will support NRG's lead drug discovery programme and the development of a novel treatment for Parkinson’s. NRG has discovered novel second-generation, mPTP inhibitors that are brain penetrant, for use in the treatment of chronic neurodegene...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 22, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $0.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NRG Therapeutics

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed

                            NRG Therapeutics

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Omega Funds

                            Deal Size : $19.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            NRG Therapeutics Announces £16 Million Series A to Advance Mitochondrial Therapeutics for Parkinson's and ALS

                            Details : The Series A proceeds will be used to advance the company's potential first-in-class brain-penetrant small molecules through IND-enabling studies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 09, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Omega Funds

                            Deal Size : $19.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            NRG Therapeutics

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed

                            NRG Therapeutics

                            United Kingdom arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Innovate Biopharmaceuticals

                            Deal Size : $3.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson's and Motor N...

                            Details : The funding will support the NRG pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson's disease (PD) and motor neuron disease (MND).

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 30, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Innovate Biopharmaceuticals

                            Deal Size : $3.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth